Press Releases

PROMETIC PRESENTS NEW CLINICAL DATA ON PBI-4050 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

PROMETIC REPORTS ITS 2018 FIRST QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC REPORTS ON ITS 2018 ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS HIGHLIGHTS

PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL

PROMETIC PRESENTS NEW PBI-4050 CLINICAL DATA FROM ONGOING ALSTRÖM SYNDROME PHASE 2 TRIAL

PROMETIC ANNOUNCES APPOINTMENT OF BRUCE WENDEL AS CHIEF BUSINESS DEVELOPMENT OFFICER

PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ONGOING PBI-4050 STUDY IN ALSTRÖM SYNDROME PATIENTS

PROMETIC REPORTS ITS Q4-2017 AND YE-2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON ACTIVITIES

PROMETIC TO REPORT ITS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND HOLD CONFERENCE CALL / WEBCAST

PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS

X